Publication: Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis
dc.contributor.author | Quispe, Cristina | |
dc.contributor.author | Herrera-Bravo, Jesus | |
dc.contributor.author | Khan, Khushbukhat | |
dc.contributor.author | Javed, Zeeshan | |
dc.contributor.author | Semwal, Prabhakar | |
dc.contributor.author | Painuli, Sakshi | |
dc.contributor.author | Martorell, Miquel | |
dc.contributor.author | Calina, Daniela | |
dc.contributor.author | Sharifi-Rad, Javad | |
dc.contributor.buuauthor | Kamiloğlu, Senem | |
dc.contributor.buuauthor | KAMİLOĞLU BEŞTEPE, SENEM | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Bilim ve Teknoloji Uygulama ve Araştırma Merkezi. | |
dc.contributor.researcherid | P-3633-2018 | |
dc.date.accessioned | 2024-10-14T13:13:04Z | |
dc.date.available | 2024-10-14T13:13:04Z | |
dc.date.issued | 2022-07-29 | |
dc.description.abstract | Medicinal applications of turmeric-derived curcumin have been known to mankind for long ages. Its potential in managing "cystic fibrosis" has also been evaluated. This autosomal recessive genetic disease is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) which involves an impaired secretion of chloride ions and leads to hypersecretion of thick and sticky mucus and serious complications including airway obstruction, chronic lung infection, and inflammatory reactions. This narrative review aims to highlight the available evidence for the efficacy of curcumin nanoformulations in its potential treatment of cystic fibrosis. Recent research has shown that curcumin acts on the localized mutant CFTR ion channel at the plasma membrane. Preclinical studies have also shown that curcumin nanoformulations have promising effects in the treatment of cystic fibrosis. In this context, the purpose of this narrative review is to highlight the general bioactivity of curcumin, the types of formulations and related studies, thus opening new therapeutic perspectives for CF. | |
dc.identifier.doi | 10.1007/s40204-022-00198-3 | |
dc.identifier.endpage | 329 | |
dc.identifier.issn | 2194-0509 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 321 | |
dc.identifier.uri | https://doi.org/10.1007/s40204-022-00198-3 | |
dc.identifier.uri | https://hdl.handle.net/11452/46391 | |
dc.identifier.volume | 11 | |
dc.identifier.wos | 000832809200001 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Springer Heidelberg | |
dc.relation.journal | Progress In Biomaterials | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Transmembrane conductance regulator | |
dc.subject | Mesoporous silica nanoparticles | |
dc.subject | Pseudomonas-aeruginosa | |
dc.subject | Plga nanoparticles | |
dc.subject | Co-delivery | |
dc.subject | Design | |
dc.subject | Expression | |
dc.subject | Strategy | |
dc.subject | Rescue | |
dc.subject | Cftr | |
dc.subject | Cystic fibrosis | |
dc.subject | Curcumin nanoparticles | |
dc.subject | Bioavailability | |
dc.subject | Molecular mechanisms | |
dc.subject | Signalling pathways | |
dc.subject | Science & technology | |
dc.subject | Technology | |
dc.subject | Engineering, biomedical | |
dc.subject | Materials science, biomaterials | |
dc.subject | Engineering | |
dc.subject | Materials science | |
dc.title | Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis | |
dc.type | Review | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 5b927446-2c67-44ca-9435-3496356c40be | |
relation.isAuthorOfPublication.latestForDiscovery | 5b927446-2c67-44ca-9435-3496356c40be |
Files
Original bundle
1 - 1 of 1